Our Brandon Gomez has more on why that move came about and why now. Hey Brandon, >> instead investors clearly seeing more haze ahead. Still, the group holding solid gains monthto date.Let's start with what actually happened yesterday. President Trump signed an executive order directing the DEA to reclassify cannabis from schedule 1 to schedule 3. Now that eases restrictions on medical research, banking, and taxes.The administration also launched a Medicare pilot program allowing some seniors starting in Apr ...

I want to emphasize that the order I am about to sign is uh not the legalization or it doesn't legalize marijuana in any way, shape or form and in no way sanctions its use as a recreational drug. Has nothing to do with it. At the same time, the facts compel the federal government to recognize that marijuana can be uh legitimate in terms of medical applications when carefully administered.In some cases, this may include the use as a substitute for addictive and potentially lethal opioid painkillers, and they ...

Some US Medicare patients would be eligible to receive coverage for CBD under an initiative being planned through the Centers for Medicare & Medicaid Services https://t.co/pfMCVCqnDG ...

Industry Focus - The cannabis and mushroom industries are converging to create billion-dollar medications [1] Company Strategy - Companies in the CBD sector are developing plans to produce medications from cannabis and mushrooms [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Industry Focus - The cannabis and psychedelic medicine industries are converging, with companies exploring the potential of both cannabis and mushrooms to create billion-dollar medications [1] Company Strategy - Companies are developing plans to create medications from cannabis and mushrooms [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Industry Focus - The CBD industry leaders are developing plans to create billion-dollar medications from cannabis and mushrooms [1]

Business Strategy - The company plans to develop billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is shifting towards the development of pharmaceuticals using cannabis and mushrooms [1]